drugset / Trial / NCT00207077
Study of Cetuximab in Combination With Tarceva in Patients With Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to find a safe and effective dose of the combination of cetuximab (Erbitux) and Tarceva (erlotinib).
Timeline
- Start
- 2005-08
- Primary completion
- 2007-05
- Completion
- 2007-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | 100 mg/m2 | Intravenous |
| Subject | Cetuximab | Monoclonal antibody | 200 mg/m2 | Intravenous |
| Subject | Cetuximab | Monoclonal antibody | 250 mg/m2 | Intravenous |
| Subject | Erlotinib | Small molecule | 150 mg | Oral |